- Title: Subtitle
- Pembrolizumab versus placebo in addition to carboplatin and paclitaxel for measurable stage 3 or 4a, stage 4b or recurrent endometrial cancer: The phase 3, NRG GY018 study (LBA 10)
- Creators
- Ramez EskanderMichael Sill - Roswell Park Cancer InstituteLindsey BeffaRichard Moore - University of Rochester Medical CenterJoanie HopeFernanda MusaRobert Mannel - University of Oklahoma Health Sciences CenterMark Shahin - Thomas Jefferson University HospitalGuilherme CantuariaEugenia Girda - Rutgers, The State University of New JerseyCara Mathews - Women & Infants Hospital of Rhode IslandJuraj Kavecansky - Kaiser PermanenteCharles Leath - University of Alabama at BirminghamLilian Gien - Sunnybrook Health Science CentreEmily Hinchcliff - Northwestern MedicineShashikant Lele - Roswell Park Cancer InstituteLisa Landrum - Indiana University HealthFloor BackesRóisín O'CearbhaillRebecca Liu - University of MichiganEmily Hill - University of IowaPremal Thaker - Washington University in St. LouisVeena John - Northwell HealthMatthew PowellCarol Aghajanian - Memorial Sloan Kettering Cancer Center
- Resource Type
- Abstract
- Publication Details
- Gynecologic oncology, Vol.176(Suppl. 1), pp.S42-S43
- DOI
- 10.1016/j.ygyno.2023.06.523
- ISSN
- 0090-8258
- eISSN
- 1095-6859
- Language
- English
- Date published
- 09/2023
- Academic Unit
- Obstetrics and Gynecology
- Record Identifier
- 9984469059102771
Abstract
Pembrolizumab versus placebo in addition to carboplatin and paclitaxel for measurable stage 3 or 4a, stage 4b or recurrent endometrial cancer: The phase 3, NRG GY018 study (LBA 10)
Gynecologic oncology, Vol.176(Suppl. 1), pp.S42-S43
09/2023
DOI: 10.1016/j.ygyno.2023.06.523
Details
Metrics
26 Record Views